869 related articles for article (PubMed ID: 24372832)
1. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
[TBL] [Abstract][Full Text] [Related]
2. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice.
Lu H; Xu XF; Gao N; Fan DY; Wang J; An J
Mol Immunol; 2013 Jun; 54(2):109-14. PubMed ID: 23270684
[TBL] [Abstract][Full Text] [Related]
4. Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice.
Gao N; Li J; Sheng Z; Chen H; Fan D; Wang P; An J
Appl Microbiol Biotechnol; 2019 Jun; 103(12):4977-4986. PubMed ID: 31037380
[TBL] [Abstract][Full Text] [Related]
5. Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone.
Li Z; Yang H; Yang J; Lin H; Wang W; Liu L; Zhao Y; Liu L; Zeng X; Yu Y; Li Y
Virus Res; 2014 Oct; 191():10-20. PubMed ID: 25091563
[TBL] [Abstract][Full Text] [Related]
6. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
[TBL] [Abstract][Full Text] [Related]
7. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
8. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
9. Comparison of infection-neutralizing and -enhancing antibody balance induced by two distinct genotype strains of dengue virus type 1 or 3 DNA vaccines in mice.
Sjatha F; Takizawa Y; Kotaki T; Yamanaka A; Konishi E
Microbes Infect; 2013 Nov; 15(12):828-36. PubMed ID: 23911844
[TBL] [Abstract][Full Text] [Related]
10. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
11. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
[TBL] [Abstract][Full Text] [Related]
12. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
[TBL] [Abstract][Full Text] [Related]
13. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.
Block OK; Rodrigo WW; Quinn M; Jin X; Rose RC; Schlesinger JJ
Vaccine; 2010 Nov; 28(51):8085-94. PubMed ID: 20959154
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
Yamanaka A; Suzuki R; Konishi E
Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
[TBL] [Abstract][Full Text] [Related]
15. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain.
Putri DH; Sudiro TM; Yunita R; Jaya UA; Dewi BE; Sjatha F; Konishi E; Hotta H; Sudarmono P
Jpn J Infect Dis; 2015; 68(5):357-63. PubMed ID: 25766602
[TBL] [Abstract][Full Text] [Related]
17. Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice.
Yamanaka A; Pitaksajjakul P; Ramasoota P; Konishi E
Vaccine; 2015 Nov; 33(45):6070-7. PubMed ID: 26259543
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens.
Kuwahara M; Konishi E
Clin Vaccine Immunol; 2010 Oct; 17(10):1560-6. PubMed ID: 20668137
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
[TBL] [Abstract][Full Text] [Related]
20. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein.
Purdy DE; Chang GJ
Virology; 2005 Mar; 333(2):239-50. PubMed ID: 15721358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
